Burkholderia cepacia nosocomial outbreak with high fatality in patients
suffering from diseases other than cystic fibrosis.
Shehabi AA, Abu-Al-Soud W, Mahafzah A, Khuri-Bulos N, Abu
Khader I, Ouis IS, Wadstrom T.
J Infect Dis. 2004;36(3):174-8.
Department of Clinical
Laboratories, Jordan University Hospital, Amman, Jordan.
Over a 1-y period,
26 inpatients at the Jordan University Hospital in Amman were
detected with bacteraemia (23 cases) or respiratory tract
colonized with B. cepacia (3 cases). A combination of genetic
identification and molecular typing has proved that all cases
were caused by a single epidemic strain of B. cepacia genomovar
IIIa. Nosocomial infections could be documented in 21/26 (81%)
patients, mostly with severe underlying or malignant diseases
other than cystic fibrosis, but the source of infection was
undetected. The overall mortality related to infection with B.
cepacia was 42%. All B. cepacia isolates were resistant to
ampicillin, amikacin, carbenicillin and gentamicin; and mostly
susceptible to piperacillin, chloramphenicol, cotri-moxazole,
tetracycline, ceftazidime, and tazocin (62-88%). This study
demonstrates the nosocomial and high fatality of B. cepacia
genomovar IIIa in Jordanian patients suffering from diseases
other than cystic fibrosis.